Trial Profile
Evaluating Efficacy and safety of subcutaneous 20% Immunoglobulin-G in patients with Polymyositis and Dermatomyositis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Feb 2016
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Dermatomyositis; Polymyositis
- Focus Therapeutic Use
- 17 Feb 2016 New trial record